Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCT

Clinical trial NCT05923814 · UNKNOWN

Trial details

NCT number: NCT05923814
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT

Start date: 2023-07-07
Primary completion: 2024-05-07
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.